Volume 9, Number 3 October 2010 - World Psychiatric Association

颐 693-710.22. Gold PW, Chrousos GP. The endocrinologyof melancholic and atypical depression: re 鄄lation to neurocircuitry and somatic conse 鄄quences. Proceedings of the Association ofAmerican Physicians 1999; 111 颐 22-34.23. Schule C. Neuroendocrinological mecha 鄄nisms of actions of antidepressant drugs. JNeuroendocrinol 2007; 19 颐 213-26.24. Mizoguchi K, Ishige A, Aburada M et al.Chronic stress attenuates glucocorticoid neg 鄄ative feedback: involvement of the prefrontalcortex and hippocampus. Neuroscience2003; 119 颐 887-97.25. Modell S, Yassouridis A, Huber J et al.Corticosteroid receptor function is decreasedin depressed patients. Neuroendocrinology1997; 65 颐 216-22.26. Young EA, Lopez JF, Murphy-Weinberg Vet al. Mineralocorticoid receptor function inmajor depression. Arch Gen Psychiatry2003; 60 颐 24-8.27. McGowan PO, Sasaki A, D 蒺 Alessio AC etal. Epigenetic regulation of the glucocorti 鄄coid receptor in human brain associates withchildhood abuse. Nature Neurosci 2009; 12颐 342-8.28. Heuser I, Yassouridis A, Holsboer F. Thecombined dexamethasone/ CRH test: a re 鄄fined laboratory test for psychiatric disor 鄄ders. J Psychiatr Res 1994; 28 颐 341-56.29. Bhagwagar Z, Hafizi S, Cowen PJ. In 鄄creased salivary cortisol after waking in de 鄄pression. Psychopharmacology 2005; 182 颐54-7.30. Schatzberg AF, Lindley S. Glucocorticoidantagonists in neuropsychiatric [ corrected]disorders. Eur J Pharmacol 2008; 583 颐 358-64.31. Nemeroff CB, Widerlov E, Bissette G etal. Elevated concentrations of CSF cortico 鄄tropin-releasing factor-like immunoreactivityin depressed patients. Science 1984; 226 颐1342-4.32. Raadsheer FC, Hoogendijk WJ, Stam FC etal. Increased numbers of corticotropinre 鄄leasing hormone expressing neurons in thehypothalamic paraventricular nucleus of de 鄄pressed patients. Neuroendocrinology 1994;60 颐 436-44.33. Nemeroff CB, Owens MJ, Bissette G et al.Reduced corticotropin releasing factor bind 鄄ing sites in the frontal cortex of suicide vic 鄄tims. Arch Gen Psychiatry 1988; 45 颐 577-9.34. Nemeroff CB. The corticotropin - releasingfactor ( CRF ) hypothesis of depression:new findings and new directions. Mol Psy 鄄chiatry 1996; 1 颐 336-42.35. Holsboer F, Ising M. Central CRH systemin depression and anxiety - evidence fromclinical studies with CRH1 receptor antago 鄄nists. Eur J Pharmacol 2008; 583 颐 350-7.36. Dantzer R, O 蒺 Connor JC, Freund GG et al.From inflammation to sickness and depres 鄄sion: when the immune system subjugatesthe brain. Nature Rev Neurosci 2008; 9 颐46-56.37. Loftis JM, Hauser P. The phenomenologyand treatment of interferon-induced depres 鄄sion. J Affect Disord 2004; 82 颐 175-90.38. Krishnan V, Nestler EJ. The molecularneurobiology of depression. Nature 2008;455 颐 894-902.39. Mendlewicz J, Kriwin P, Oswald P et al.Shortened onset of action of antidepressantsin major depression using acetylsalicylic acidaugmentation: a pilot open-label study. IntClin Psychopharmacol 2006; 21 颐 227-31.40. Nemeroff CB, Heim CM, Thase ME et al.Differential responses to psychotherapy ver 鄄sus pharmacotherapy in patients with chronicforms of major depression and childhoodtrauma. Proc Natl Acad Sci USA 2003; 100颐 14293-6.41. Neumeister A, Konstantinidis A, Stastny Jet al. Association between serotonin trans 鄄porter gene promoter polymorphism(5HTTLPR ) and behavioral responses totryptophan depletion in healthy women withand without family history of depression.Arch Gen Psychiatry 2002; 59 颐 613-20.42. Neumeister A, Nugent AC, Waldeck T etal. Neural and behavioral responses to tryp 鄄tophan depletion in unmedicated patientswith remitted major depressive disorder andcontrols. Arch Gen Psychiatry 2004; 61 颐765-73.43. Drevets WC, Frank E, Price JC et al. PETimaging of serotonin 1A receptor binding indepression. Biol Psychiatry 1999; 46 颐 1375-87.44. Neumeister A, Bain E, Nugent AC et al.Reduced serotonin type 1A receptor bindingin panic disorder. J Neurosci 2004; 24 颐589-91.45. Hasler G, Bonwetsch R, Giovacchini G etal 郾 5 - HT1A receptor binding in temporallobe epilepsy patients with and without majordepression. Biol Psychiatry 2007; 62 颐 1258-64.46. Meyer JH, Ginovart N, Boovariwala A etal. Elevated monoamine oxidase A levels inthe brain: an explanation for the monoamineimbalance of major depression. Arch GenPsychiatry 2006; 63 颐 1209-16.47. Zhang X, Gainetdinov RR, Beaulieu JM etal. Loss-of-function mutation in tryptophanhydroxylase- 2 identified in unipolar majordepression. Neuron 2005; 45 颐 11-6.48. Charney DS, Manji HK. Life stress,genes, and depression: multiple pathwayslead to increased risk and new opportunitiesfor intervention. Sci STKE 2004; 2004颐 re5.49. Pandey GN, Dwivedi Y. Noradrenergicfunction in suicide. Arch Suicide Res 2007;11 颐 235-46.50. Nutt DJ. The role of dopamine and norepi 鄄nephrine in depression and antidepressanttreatment. J Clin Psychiatry 2006; 67(Suppl 郾 6) 颐 3-8.51. Goldberg JF, Burdick KE, Endick CJ.Preliminary randomized, double - blind,placebo-controlled trial of pramipexole add 鄄ed to mood stabilizers for treatment-resistantbipolar depression. Am J Psychiatry 2004;161 颐 564-6.52. Lambert G, Johansson M, Agren H et al.Reduced brain norepinephrine and dopaminerelease in treatment-refractory depressive ill 鄄ness: evidence in support of the cate 鄄cholamine hypothesis of mood disorders.Arch Gen Psychiatry 2000; 57 颐 787-93.53. Meyer JH, Kruger S, Wilson AA et al.Lower dopamine transporter binding potentialin striatum during depression. Neuroreport2001; 12 颐 4121-5.54. Santamaria J, Tolosa E, Valles A.Parkinson 蒺 s disease with depression: a pos 鄄sible subgroup of idiopathic parkinsonism.Neurology 1986; 36 颐 1130-3 郾 16155. Hasler G, Fromm S, Carlson PJ et al.Neural response to catecholamine depletionin unmedicated subjects with major depres 鄄sive disorder in remission and healthy sub 鄄jects. Arch Gen Psychiatry 2008; 65 颐 521-31.56. Hasler G, Luckenbaugh DA, Snow J et al.摇 160世 界 精 神 病 学 9: 3-2010 年 10 月